Literature DB >> 18418354

Xenotransplantation: where are we in 2008?

B Sprangers1, M Waer, A D Billiau.   

Abstract

Xenotransplantation holds promise to solve the ever increasing shortage of donor organs for allotransplantation. In the last 2 decades, major progress has been made in understanding the immunobiology of pig-into-(non)human primate transplantation and today we are on the threshold of the first clinical trials. Hyperacute rejection, which is mediated by pre-existing anti-alpha Gal xenoreactive antibodies, can in non-human primates be overcome by complement- and/or antibody-modifying interventions. A major step forward was the development of genetically engineered pigs, either transgenic for human complement regulatory proteins or deficient in the alpha1,3-galactosyltranferase enzyme. However, several other immunologic and nonimmunologic hurdles remain. Acute vascular xenograft rejection is mediated by humoral and cellular mechanisms. Elicited xenoreactive antibodies play a key role. In addition to providing B cell help, xenoreactive T cells may directly contribute to xenograft rejection. Long-term survival of porcine kidney- and heart xenografts in non-human primates has been obtained but required severe T and B cell immunosuppression. Induction of xenotolerance, e.g. through mixed hematopoietic chimerism, may represent the preferred approach, but although proof of principle has been delivered in rodents, induction of pig-to-non-human primate chimerism remains problematic. Finally, it is now clear that innate immune cells, in particular macrophages and natural killer cells, can mediate xenograft destruction, the determinants of which are being elucidated. Chronic xenograft rejection is not well understood, but recent studies indicate that non-immunological problems, such as incompatibilities between human procoagulant and pig anticoagulant components may play an important role. Here, we give a comprehensive overview of the currently known obstacles to xenografting: immune and non-immune problems are discussed, as well as the possible strategies that are under development to overcome these hurdles.

Entities:  

Mesh:

Year:  2008        PMID: 18418354     DOI: 10.1038/ki.2008.135

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  13 in total

Review 1.  Genetically modified pigs for biomedical research.

Authors:  Yonglun Luo; Lin Lin; Lars Bolund; Thomas G Jensen; Charlotte Brandt Sørensen
Journal:  J Inherit Metab Dis       Date:  2012-03-28       Impact factor: 4.982

2.  Production of heterozygous alpha 1,3-galactosyltransferase (GGTA1) knock-out transgenic miniature pigs expressing human CD39.

Authors:  Kimyung Choi; Joohyun Shim; Nayoung Ko; Heejong Eom; Jiho Kim; Jeong-Woong Lee; Dong-Il Jin; Hyunil Kim
Journal:  Transgenic Res       Date:  2016-11-09       Impact factor: 2.788

Review 3.  Concise review: Kidney stem/progenitor cells: differentiate, sort out, or reprogram?

Authors:  Oren Pleniceanu; Orit Harari-Steinberg; Benjamin Dekel
Journal:  Stem Cells       Date:  2010-09       Impact factor: 6.277

Review 4.  Pig liver xenotransplantation as a bridge to allotransplantation: which patients might benefit?

Authors:  Burcin Ekser; Bruno Gridelli; A Joseph Tector; David K C Cooper
Journal:  Transplantation       Date:  2009-11-15       Impact factor: 4.939

Review 5.  Update: cardiac xenotransplantation.

Authors:  Burcin Ekser; David Kc Cooper
Journal:  Curr Opin Organ Transplant       Date:  2008-10       Impact factor: 2.640

6.  Porcine Knock-in Fibroblasts Expressing hDAF on α-1,3-Galactosyltransferase (GGTA1) Gene Locus.

Authors:  Ji Woo Kim; Hye-Min Kim; Sang Mi Lee; Man-Jong Kang
Journal:  Asian-Australas J Anim Sci       Date:  2012-10       Impact factor: 2.509

7.  Generation and characterization of a transgenic pig carrying a DsRed-monomer reporter gene.

Authors:  Chih-Jen Chou; Shao-Yu Peng; Mei-Han Wu; Cho-Chen Yang; Yu-Sheng Lin; Winston Teng-Kui Cheng; Shinn-Chih Wu; Yao-Ping Lin
Journal:  PLoS One       Date:  2014-09-04       Impact factor: 3.240

8.  Xenograft Failure of Pulmonary Valved Conduit Cross-linked with Glutaraldehyde or Not Cross-linked in a Pig to Goat Implantation Model.

Authors:  Dong Jin Kim; Yong Jin Kim; Woong-Han Kim; Soo-Hwan Kim
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2012-10-09

9.  Pancreatic islet xenograft survival in mice is extended by a combination of alpha-1-antitrypsin and single-dose anti-CD4/CD8 therapy.

Authors:  Efrat Ashkenazi; Boris M Baranovski; Galit Shahaf; Eli C Lewis
Journal:  PLoS One       Date:  2013-05-22       Impact factor: 3.240

10.  Production of multiple transgenic Yucatan miniature pigs expressing human complement regulatory factors, human CD55, CD59, and H-transferase genes.

Authors:  Young-Hee Jeong; Chi-Hun Park; Gun-Hyuk Jang; Yeun-Ik Jeong; In-Sung Hwang; Yeon-Woo Jeong; Yu-Kyung Kim; Taeyoung Shin; Nam-Hyung Kim; Sang-Hwan Hyun; Eui-Bae Jeung; Woo-Suk Hwang
Journal:  PLoS One       Date:  2013-05-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.